Acts as a substrate for VE-PTP and is required by it to stimulate VE-cadherin function in endothelial cells. Can replace beta-catenin in E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton.
| Inventor | Institute |
|---|---|
| Fiona Watt | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| SKU: | 153350 |
|---|---|
| Product description: | Plakoglobin is a common junctional plaque protein. The membrane-associated plaques are architectural elements in an important strategic position to influence the arrangement and function of both the cytoskeleton and the cells within the tissue. The presence of plakoglobin in both the desmosomes and in the intermediate junctions suggests that it plays a central role in the structure and function of submembranous plaques. Acts as a substrate for VE-PTP and is required by it to stimulate VE-cadherin function in endothelial cells. Can replace beta-catenin in E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton. |
| Alternate name: | Gamma Catenin |
| Conjugation: | Unconjugated |
| Immunogen: | Peptide – NH2-CIDTYSDGLRPPYPTADH-COOH |
| Cat. #: | 153350 |
|---|---|
| Provenance and Ownership: | The Anti-Plakoglobin [VB3] is owned by Cancer Research UK. CancerTools supplies the Anti-Plakoglobin [VB3] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-Plakoglobin [VB3] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology |
| Application: | IP ; IF ; IP ; WB |
| Target: | Plakoglobin |
| Reactivity: | Human ; Mouse |
| Clone: | VB3 |
| Host: | Rabbit |
| Class: | Polyclonal |
| Target background: | Plakoglobin is a common junctional plaque protein. The membrane-associated plaques are architectural elements in an important strategic position to influence the arrangement and function of both the cytoskeleton and the cells within the tissue. The presence of plakoglobin in both the desmosomes and in the intermediate junctions suggests that it plays a central role in the structure and function of submembranous plaques. Acts as a substrate for VE-PTP and is required by it to stimulate VE-cadherin function in endothelial cells. Can replace beta-catenin in E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | Serum |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Erasmus et al. 2016. Nat Commun. 7:13542. PMID: 27922008. Defining Fn interactions during biogenesis of epithelial junctions. Ryan et al. 2012. J Cell Sci. 125(Pt 13):3202-9. PMID: 22454524. Plakoglobin-dependent regulation of keratinocyte apoptosis by Rnd3. Zhu et al. 1999. Development. 126(10):2285-98. PMID: 10207152. beta-catenin signalling modulates proliferative potential of human epidermal keratinocytes independently of intercellular adhesion. Braga et al. 1995. Cell Adhes Commun. 3(3):201-15. PMID: 8846022. Calcium-induced changes in distribution and solubility of cadherins, integrins and their associated cytoplasmic proteins in human keratinocytes. NĤthke et al. 1994. J Cell Biol. 125(6):1341-52. PMID: 8207062. Defining interactions and distributions of cadherin and catenin complexes in polarized epithelial cells. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.